Shots:

• HiFiBiO to receive $25M up front- option exercise payment and is eligible to receive ~$1.1B as a future option- clinical- regulatory & commercial milestone across all three programs along with royalties based upon WW net sales
• FibroGen exclusively licenses all products in HiFiBiO’s Galectin-9 program and will have sole right to develop globally & also obtained an exclusive option to their CXCR5 and CCR8 programs
• If an option is exercised- FibroGen will have the right to develop products from Galectin-9 program globally. The lead product candidate in the Galectin-9 program is expected to enter clinical development in Q1’23 while CXCR5 and CCR8 programs in the mid 2023

  | Ref: Globe Newswire | Image: FibroGen